tirzepatide in indianapolis https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound Renew Vitality Testosterone Clinic of

Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound during pregnancy

Results may vary based on starting weight and program adherence

Recently announced topline results from the 40-week SURPASS-2 trial show that the highest tirzepatide dose of 15 mg was associated with an A1C reduction by 2.46% and a body weight reduction by 13.1%

x Compounded drugs are permitted to be prescribed under federal law, but are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review

Insurance does not typically cover these medications

INDICATION AND SAFETY SUMMARY WITH WARNINGS Zepbound (ZEHP-bownd) is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off